EYPT vs FDMT

EyePoint, Inc. vs 4D Molecular Therapeutics, Inc. — Valuation Comparison 2026

EYPT

Biotechnology
EyePoint, Inc.
Quality
5.6
out of 10
Value Trap
12
SAFE
Price
$13.50
Last close
Models
9/13
Active
VS

FDMT

Biotechnology
4D Molecular Therapeutics, Inc.
Quality
7.1
out of 10
Value Trap
24
SAFE
Price
$8.97
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType EYPT Fair ValueEYPT Upside FDMT Fair ValueFDMT Upside
Bayesian DCF Intrinsic $4.03 -70.2% $3.01 -66.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.13 -69.4% $8.24 -8.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EYPT vs FDMT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EYPT vs FDMT — Which Stock Is More Undervalued?

FDMT scores higher with a 7.1/10 quality rating vs EYPT's 5.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing EyePoint, Inc. (EYPT) and 4D Molecular Therapeutics, Inc. (FDMT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EYPT currently trades at $13.50 with a QOC of 5.6/10, while FDMT trades at $8.97 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).